Inhibrx Biosciences, Inc. Common Stock (INBX) is a publicly traded Healthcare sector company. As of May 21, 2026, INBX trades at $106.96 with a market cap of $1.55B and a P/E ratio of -13.02. INBX moved +0.42% today. Year to date, INBX is +43.09%; over the trailing twelve months it is +741.70%. Its 52-week range spans $10.81 to $155.29. Analyst consensus is buy with an average price target of $277.50. Rallies surfaces INBX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Inhibrx Raises Cash to $161.7M, Narrows Loss and Reveals Phase II Data: Inhibrx ended Q1 2026 with $161.7M in cash after a $75M loan amendment and cut its net loss to $33.4M ($2.15/share) from $43.3M. The firm announced updated interim Phase II data for INBRX-106, filed a BLA for ozekibart in chondrosarcoma and plans a registrational CRC trial.
| Metric | Value |
|---|---|
| Price | $106.96 |
| Market Cap | $1.55B |
| P/E Ratio | -13.02 |
| EPS | $-8.39 |
| Dividend Yield | 0.00% |
| 52-Week High | $155.29 |
| 52-Week Low | $10.81 |
| Volume | 3 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.30M |
| Net Income | $-130.19M |
| Gross Margin | 0.00% |
2 analysts cover INBX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $277.50.